Wang Shilong, Yin Ming, Xia Zhichao
Department of Ultrasound, The Affiliated Taizhou People's Hospital of Nanjing Medical University, Taizhou, China.
Department of Clinical and Research, Shenzhen Mindray Biomedical Electronics Co., Ltd., Shenzhen, China.
J Gastrointest Oncol. 2023 Feb 28;14(1):265-277. doi: 10.21037/jgo-23-16. Epub 2023 Feb 23.
To study the curative effect of sclerotherapy with lauromacrogol on a rabbit VX2 implanted liver tumor model, the effect of ultrasound-guided sclerotherapy with different doses of lauromacrogol in the treatment of the rabbit VX2 implanted liver tumor model and the degree of damage to the surrounding liver tissue was compared and observed. The relationship between the sclerosing effect and drug dose of lauromacrogol in the treatment of liver cancer is preliminarily discussed.
Thirty rabbit models of liver cancer were randomly divided into 5 groups. Control Group A was injected with normal saline, control Group B was injected with absolute ethanol, experimental Group C was injected with lauromacrogol (Z =2.885D); the injection volume in experimental Group D was 1.5-fold higher than that in Group C; and the injection volume in experimental Group E was 2-fold higher than that in Group C. Changes in tumor volume were followed up by ultrasound before and 7 and 14 days after the operation; contrast-enhanced ultrasonography was used to measure the volume of the ablation area and volume rate. For pathological anatomy, hematoxylin and eosin (H&E) staining were used to observe tumor cell necrosis and the degree of damage to surrounding normal liver cells. The expression levels of the apoptosis-related protein cleaved-caspase 3 and the cell proliferation antigen Ki67 were examined by immunohistochemistry.
The volumes in Groups A and C increased significantly. The volumes in Groups B, D, and E remained the same or slightly expanded, tumor growth in the three groups was significantly inhibited after sclerotherapy. Contrast-enhanced ultrasonography showed that the ablation volume and ablation volume rate in Groups B, D, and E were similar. Group C were smaller than those in the other treatment groups. Large coagulative necrotic foci were observed in the central area of tumors in Groups B, D, and E.
The experiment demonstrates that lauromacrogol can inhibit tumor growth in the rabbit VX2 tumor model and cause VX2 tumor cell apoptosis. The sclerosing effect of the 1.5-fold amount of lauromacrogol is equivalent to that of absolute ethanol, with little effect on normal liver tissue.
为研究聚桂醇硬化治疗兔VX2移植性肝肿瘤模型的疗效，比较观察不同剂量聚桂醇超声引导下硬化治疗兔VX2移植性肝肿瘤模型的效果及对周围肝组织的损伤程度，初步探讨聚桂醇治疗肝癌时硬化效果与药物剂量的关系。
将30只兔肝癌模型随机分为5组。A对照组注射生理盐水，B对照组注射无水乙醇，C实验组注射聚桂醇（Z =2.885D）；D实验组注射量为C组的1.5倍；E实验组注射量为C组的2倍。术后7天及14天超声随访肿瘤体积变化；采用超声造影测量消融区体积及体积率。病理解剖采用苏木精-伊红（H&E）染色观察肿瘤细胞坏死及周围正常肝细胞损伤程度。免疫组化检测凋亡相关蛋白cleaved-caspase 3及细胞增殖抗原Ki67的表达水平。
A组和C组体积明显增大。B组、D组和E组体积保持不变或略有增大，硬化治疗后三组肿瘤生长均明显受抑制。超声造影显示，B组、D组和E组的消融体积及消融体积率相近。C组小于其他治疗组。B组、D组和E组肿瘤中央区可见大片凝固性坏死灶。
实验表明，聚桂醇可抑制兔VX2肿瘤模型肿瘤生长并引起VX2肿瘤细胞凋亡。1.5倍量聚桂醇的硬化效果与无水乙醇相当，对正常肝组织影响较小。
